Dataset Information

Evaluating the Alzheimer's disease data landscape.

ABSTRACT:

Introduction

Numerous studies have collected Alzheimer's disease (AD) cohort data sets. To achieve reproducible, robust results in data-driven approaches, an evaluation of the present data landscape is vital.

Methods

Previous efforts relied exclusively on metadata and literature. Here, we evaluate the data landscape by directly investigating nine patient-level data sets generated in major clinical cohort studies.

Results

The investigated cohorts differ in key characteristics, such as demographics and distributions of AD biomarkers. Analyzing the ethnoracial diversity revealed a strong bias toward White/Caucasian individuals. We described and compared the measured data modalities. Finally, the available longitudinal data for important AD biomarkers was evaluated. All results are explorable through our web application ADataViewer (https://adata.scai.fraunhofer.de).

Discussion

Our evaluation exposed critical limitations in the AD data landscape that impede comparative approaches across multiple data sets. Comparison of our results to those gained by metadata-based approaches highlights that thorough investigation of real patient-level data is imperative to assess a data landscape.

SUBMITTER: Birkenbihl C

PROVIDER: S-EPMC7744022 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Evaluating the Alzheimer's disease data landscape.

Birkenbihl Colin C Salimi Yasamin Y Domingo-Fernándéz Daniel D Lovestone Simon S Fröhlich Holger H Hofmann-Apitius Martin M

Alzheimer's & dementia (New York, N. Y.) 20201216 1

<h4>Introduction</h4>Numerous studies have collected Alzheimer's disease (AD) cohort data sets. To achieve reproducible, robust results in data-driven approaches, an evaluation of the present data landscape is vital.<h4>Methods</h4>Previous efforts relied exclusively on metadata and literature. Here, we evaluate the data landscape by directly investigating nine patient-level data sets generated in major clinical cohort studies.<h4>Results</h4>The investigated cohorts differ in key characteristic ...[more]

PMID: 33344750

Similar Datasets

Project description:BackgroundAlzheimer's disease (AD) is a devastating neurodegenerative disease leading to dementia. The field has made significant progress over the last 15 years. AD diagnosis has shifted from syndromal, based on signs and symptoms, to a biomarker construct based on the pathological hallmarks of the disease: amyloid β deposition, pathologic tau, and neurodegeneration. Numerous genetic risk factors for sporadic AD have been identified, providing further insight into the molecular underpinnings of the disease. For the last two decades, however, drug development for AD has been proven to be particularly challenging. Here, we provide a unique overview of the drug development landscape for AD. By comparing preclinical and clinical drug development pipelines, we aim to describe trends and differences regarding target classes and therapeutic modalities in preclinical and clinical development.MethodsWe analyzed proprietary and public databases and company websites for drugs in preclinical development for AD by the pharmaceutical industry and major clinical trial registries for drugs in clinical development for AD. Drugs were categorized by target class and treatment modality.ResultsWe found a higher proportion of preclinical interventions targeting molecular pathways associated with sporadic AD genetic risk variants, compared to clinical stage interventions. These include apolipoprotein E (ApoE) and lipids, lysosomal/endosomal targets, and proteostasis. Further, we observed a trend suggesting that more traditional therapeutic modalities are developed for these novel targets, while more novel treatment modalities such as gene therapies and enzyme treatments are in development for more traditional targets such as amyloid β and tau. Interestingly, the percentage of amyloid β targeting therapies in preclinical development (19.2%) is even higher than the percentage in clinical development (10.7%), indicating that diversification away from interventions targeting amyloid-beta has not materialized. Inflammation is the second most popular target class in both preclinical and clinical development.ConclusionsOur observations show that the AD drug development pipeline is diversifying in terms of targets and treatment modalities, while amyloid-targeting therapies remain a prominent avenue of development as well. To further advance AD drug development, novel companion diagnostics are needed that are directed at disease mechanisms related to genetic risk factors of AD, both for patient stratification and assessment of therapeutic efficacy in clinical trials.

Project description:Chronic glial activation and neuroinflammation induced by the amyloid-β peptide (Aβ) contribute to Alzheimer's disease (AD) pathology. APOE4 is the greatest AD-genetic risk factor; increasing risk up to 12-fold compared to APOE3, with APOE4-specific neuroinflammation an important component of this risk. This editorial review discusses the role of APOE in inflammation and AD, via a literature review, presentation of novel data on Aβ-induced neuroinflammation, and discussion of future research directions. The complexity of chronic neuroinflammation, including multiple detrimental and beneficial effects occurring in a temporal and cell-specific manner, has resulted in conflicting functional data for virtually every inflammatory mediator. Defining a neuroinflammatory phenotype (NIP) is one way to address this issue, focusing on profiling the changes in inflammatory mediator expression during disease progression. Although many studies have shown that APOE4 induces a detrimental NIP in peripheral inflammation and Aβ-independent neuroinflammation, data for APOE-modulated Aβ-induced neuroinflammation are surprisingly limited. We present data supporting the hypothesis that impaired apoE4 function modulates Aβ-induced effects on inflammatory receptor signaling, including amplification of detrimental (toll-like receptor 4-p38α) and suppression of beneficial (IL-4R-nuclear receptor) pathways. To ultimately develop APOE genotype-specific therapeutics, it is critical that future studies define the dynamic NIP profile and pathways that underlie APOE-modulated chronic neuroinflammation. In this editorial review, we present data supporting the hypothesis that impaired apoE4 function modulates Aβ-induced effects on inflammatory receptor signaling, including amplification of detrimental (TLR4-p38α) and suppression of beneficial (IL-4R-nuclear receptor) pathways, resulting in an adverse NIP that causes neuronal dysfunction. NIP, Neuroinflammatory phenotype; P.I., pro-inflammatory; A.I., anti-inflammatory.

Dataset Information

Evaluating the Alzheimer's disease data landscape.

Introduction

Methods

Results

Discussion

Publications

Evaluating the Alzheimer's disease data landscape.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets